Difference between revisions of "B-cell lymphoma of mucosa-associated lymphoid tissue - null regimens"
Jump to navigation
Jump to search
(Created page with "<span id="BackToTop"></span> <div class="noprint" style="background-color:LightGray; position:fixed; bottom:2%; right:0.25%; padding-left:5px; padding-right:5px; margin: 15px;...") |
m (→Regimen) |
||
| Line 20: | Line 20: | ||
|1995-2001 | |1995-2001 | ||
|style="background-color:#1a9851"|Phase 3 (C) | |style="background-color:#1a9851"|Phase 3 (C) | ||
| − | |[[B- | + | |[[B-cell_lymphoma_of_mucosa-associated_lymphoid_tissue_-_historical#Chlorambucil_monotherapy|Chlorambucil]] |
| style="background-color:#ffffbf" |Did not meet primary endpoint of RR | | style="background-color:#ffffbf" |Did not meet primary endpoint of RR | ||
|- | |- | ||
| Line 29: | Line 29: | ||
*[[#Helicobacter_pylori_eradication_therapy|H. pylori eradication therapy]] | *[[#Helicobacter_pylori_eradication_therapy|H. pylori eradication therapy]] | ||
</div></div> | </div></div> | ||
| + | |||
===References=== | ===References=== | ||
# '''LY03:''' Hancock BW, Qian W, Linch D, Delchier JC, Smith P, Jakupovic I, Burton C, Souhami R, Wotherspoon A, Copie-Bergman C, Capella C, Traulle C, Levy M, Cortelazzo S, Ferreri AJ, Ambrosetti A, Pinotti G, Martinelli G, Vitolo U, Cavalli F, Gisselbrecht C, Zucca E. Chlorambucil versus observation after anti-Helicobacter therapy in gastric MALT lymphomas: results of the international randomised LY03 trial. Br J Haematol. 2009 Feb;144(3):367-75. Epub 2008 Nov 22. [https://doi.org/10.1111/j.1365-2141.2008.07486.x link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2659366/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/19036078/ PubMed] [https://clinicaltrials.gov/study/NCT00003617 NCT00003617] | # '''LY03:''' Hancock BW, Qian W, Linch D, Delchier JC, Smith P, Jakupovic I, Burton C, Souhami R, Wotherspoon A, Copie-Bergman C, Capella C, Traulle C, Levy M, Cortelazzo S, Ferreri AJ, Ambrosetti A, Pinotti G, Martinelli G, Vitolo U, Cavalli F, Gisselbrecht C, Zucca E. Chlorambucil versus observation after anti-Helicobacter therapy in gastric MALT lymphomas: results of the international randomised LY03 trial. Br J Haematol. 2009 Feb;144(3):367-75. Epub 2008 Nov 22. [https://doi.org/10.1111/j.1365-2141.2008.07486.x link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2659366/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/19036078/ PubMed] [https://clinicaltrials.gov/study/NCT00003617 NCT00003617] | ||
Latest revision as of 12:08, 5 November 2023
The purpose of this page is to provide references to "null therapy" such as placebo and observation. These references provide further insight into the historical development of the treatment landscape. See the main MALT lymphoma page for regimens that include active anticancer treatment.
Consolidation after first-line therapy
Observation
Regimen
| Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Hancock et al. 2008 (LY03) | 1995-2001 | Phase 3 (C) | Chlorambucil | Did not meet primary endpoint of RR |
No further treatment.
Preceding treatment
References
- LY03: Hancock BW, Qian W, Linch D, Delchier JC, Smith P, Jakupovic I, Burton C, Souhami R, Wotherspoon A, Copie-Bergman C, Capella C, Traulle C, Levy M, Cortelazzo S, Ferreri AJ, Ambrosetti A, Pinotti G, Martinelli G, Vitolo U, Cavalli F, Gisselbrecht C, Zucca E. Chlorambucil versus observation after anti-Helicobacter therapy in gastric MALT lymphomas: results of the international randomised LY03 trial. Br J Haematol. 2009 Feb;144(3):367-75. Epub 2008 Nov 22. link to original article link to PMC article PubMed NCT00003617